Please Wait
Applying Filters...
menu
    • menu
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

    Stock Recap
    #PipelineProspector

    Menu

    Daclatasvir

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 654Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Name of the Firm Written Confirmation No. Product Name Issue Date Valid Till Address of the Firm
    18/11/2024 Cipla
    India
    		 M/s. Cipla Ltd WC-0142n Daclatasvir Dihydrochloride IH 2022-06-17 2025-08-04 Plot. A-33, A-37/2/2 MIDC, Patalganga-410 220, Dist. Raigad, Maharashtra
    18/11/2024 Glenmark Life Sciences
    India
    		 M/s Glenmark Life Sciences Limited WC-0310 Daclatasvir Dihydrochloride IH 2023-12-28 2026-12-28 Plot No. Z-103/l, Dahej SEZ, Phase ll, Dahej, Dist-Bharuch, Gujarat